ClinicaliQ Trial Snapshot
- Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism — Active Not Recruiting • Phase III • Diabetes / Metabolic • NCT03941236.
- Long-term safety study of dasiglucagon injections in children with congenital hyperinsulinism, following earlier trial completion.
- (Word count: 19).
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is an open-label, multinational, multicenter, long-term safety and efficacy extension trial in patients with Congenital Hyperinsulinism (CHI) who completed either ZP4207-17103 (NCT04172441) or ZP4207-17109 (NCT03777176) (defined as lead-in trials). The primary objective is to evaluate the long-term safety of dasiglucagon administered as a subcutaneous (SC) infusion in children with CHI. Conditions: Congenital Hyperinsulinism Interventions: dasiglucagon Lead Sponsor: Zealand Pharma Planned Enrollment: 42 participants